Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas

被引:63
作者
Engelsen, Ingeborg B. [1 ]
Stefansson, Ingunn
Aksten, Lars A.
Salvesen, Helga B.
机构
[1] Haukeland Univ Hosp, Dept Obstet & Gynecol, N-5021 Bergen, Norway
[2] Haukeland Univ Hosp, Dept Pathol, N-5021 Bergen, Norway
[3] Univ Bergen, Gade Inst, Bergen, Norway
[4] Univ Bergen, Inst Clin Med, Bergen, Norway
关键词
endometrial carcinoma; curettage material; tumor markers; prognosis; survival;
D O I
10.1016/j.ajog.2006.02.045
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: The purpose of this study was to investigate the prognostic impact of p53 and p16 expression in curettage material from patients with endometrial carcinoma. Study design: Preoperative curettage material from a population-based series of 236 endometrial carcinomas from Norway with long and complete follow-up was studied immunohistochemically for p53 and p 16 expression. Results: Pathologic expression of p53 and p16 was seen in 24% and 25%, respectively, and was significantly correlated with high International Federation of Gynecology and Obstetrics (FIGO) stage and serous/clear cell histologic subtypes. Pathologic p53 expression showed significant correlation with postmenopausal status, high grade, high tumor cell proliferation, and aneuploidy. Patients with normal expression had 85% 5-year survival compared with 51% and 50% when pathologic expression of p53 and p16, respectively. Five-year survival for patients with 2 pathologic markers was 13%, compared with 67% and 91% for 1 or no pathologic markers, respectively. Conclusion: Pathologic expression of p53 and p16 in curettage material identifies high-risk endometrial carcinoma patients with poor prognosis. (c) 2006 Mosby, Inc. All rights reserved.
引用
收藏
页码:979 / 986
页数:8
相关论文
共 32 条
  • [11] *I EP CANC RES, 1999, CANC REG NORW CANC N
  • [12] Cell-cycle control and its watchman
    Jacks, T
    Weinberg, RA
    [J]. NATURE, 1996, 381 (6584) : 643 - 644
  • [13] KILGORE LC, 2005, INT J GYNECOL CANCER, V15, P406
  • [14] RELIABILITY OF TUMOR TYPING OF ENDOMETRIAL CARCINOMA IN PREHYSTERECTOMY CURETTAGE
    LAMPE, B
    KURZL, R
    HANTSCHMANN, P
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1995, 14 (01) : 2 - 6
  • [15] COMPARISON OF D-AND-C AND OFFICE ENDOMETRIAL BIOPSY IN PREDICTING FINAL HISTOPATHOLOGIC GRADE IN ENDOMETRIAL CANCER
    LARSON, DM
    JOHNSON, KK
    BROSTE, SK
    KRAWISZ, BR
    KRESL, JJ
    [J]. OBSTETRICS AND GYNECOLOGY, 1995, 86 (01) : 38 - 42
  • [16] Comparison of estrogen and progesterone receptor, Ki-67, and p53 immunoreactivity in uterine endometrioid carcinoma and endometrioid carcinoma with squamous, mucinous, secretory, and ciliated cell differentiation
    Lax, SF
    Pizer, ES
    Ronnett, BM
    Kurman, RJ
    [J]. HUMAN PATHOLOGY, 1998, 29 (09) : 924 - 931
  • [17] SURGICAL PATHOLOGICAL STAGING IN APPARENT STAGE-I ENDOMETRIAL CARCINOMA
    MANGIONI, C
    DEPALO, G
    MARUBINI, E
    DELVECCHIO, M
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1993, 3 (06) : 373 - 384
  • [18] Endometrial cancer: can nodal status be predicted with curettage?
    Mariani, A
    Sebo, TJ
    Katzmann, JA
    Roche, PC
    Keeney, GL
    Lesnick, TG
    Podratz, KC
    [J]. GYNECOLOGIC ONCOLOGY, 2005, 96 (03) : 594 - 600
  • [19] Pretreatment assessment of prognostic indicators in endometrial cancer
    Mariani, A
    Sebo, TJ
    Katzmann, JA
    Keeney, GL
    Roche, PC
    Lesnick, TG
    Podratz, KC
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2000, 182 (06) : 1535 - 1543
  • [20] NORUSIS M, 1994, SPSS ADVANCED STAT 6